Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer

Breast Cancer Research

Table 1 Univariable and multivariable Cox model for progression-free survival

	Univariable		Multivariable
	Item	p value	HR	95% CI	p value	Status	n (%)
Clinical	Lines of prior treatment	0.0278	1.43	1.02–1.99	0.0360	0	18 (26)
	(adjuvant treatment as one line if applicable)					1	25 (36)
						2–3	13 (19)
						≥ 4	13 (19)
Mutation	PIK3CA	0.0086	5.53	2.41–12.71	5.60E–05	Mutated	27 (39)
	PIK3CA or ERBB2	0.0100
	CDK12	0.0135	3.47	1.12–10.73	0.0310	Mutated	9 (13)
	HMCN1	0.0200
	CACNA1G	0.0285
Signatures	DBS3	0.0009	18.07	5.71–57.17	8.50E−07	> 10% contribution	8 (12)
	SBS18	0.0210
	SBS39	0.0239
	SBS40	0.0417
	SV6	0.0407
Copy numbers	Gain 8p11.23	0.0105	3.91	1.91–8.03	0.0002	Present	24 (35)
	WGD	0.0286

HR hazard ratio, CI confidence interval
*Items that reached statistical significance (p < 0.05) were used in a multivariable Cox regression to model outcome on anti-HER2-targeted therapy post-biopsy. All variables were used as categorical variable: number or prior lines was divided in 4 groups, mutations and copy numbers were grouped as yes/no, and signatures were grouped in above/below median

ISSN: 1465-542X